ENZ - Enzo Biochem Inc: Wildly Undervalued COVID-19 Test Play With Near-Term Catalysts
Investment Thesis
Enzo Biochem, Inc. (ENZ) is a vertically integrated life sciences company focusing on developing unique diagnostic platform technologies. Specific to the outbreak of COVID-19, ENZ also provides both molecular and serology tests in New York, New Jersey, and Connecticut.
ENZ has not benefited from its COVID-19 exposure and its stock is down 17% year-to-date (see charts below) while its small-cap peers are up from 7% to 1,432%.
ENZ at current levels is mispriced and undervalued given its significant revenue potential over the next twelve months, driven by the recent granting of